Research Frontiers Inc. Receives Nasdaq Deficiency Notices: Critical Updates for Investors
Research Frontiers Incorporated (NASDAQ: REFR) has announced that on June 2, 2026, it received two deficiency notification letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). These notifications relate to the company’s failure to satisfy two key continued listing requirements. This development is significant and could have material implications for shareholders and the company’s share value.
Key Points from the 8-K Filing
- Minimum Bid Price Requirement: The first letter stated that REFR’s common stock had closed below the \$1.00 minimum bid price for 30 consecutive business days (from April 15, 2026 to June 1, 2026), violating Nasdaq Listing Rule 5550(a)(2).
- Minimum Market Value of Listed Securities (MVLS) Requirement: The second letter advised that REFR’s Market Value of Listed Securities had remained below the \$35 million threshold for 30 consecutive business days (from April 20, 2026 to June 1, 2026), violating Nasdaq Listing Rule 5550(b)(2).
- No Alternative Compliance: The notification further highlighted that the company does not currently meet alternative standards, including minimum stockholders’ equity and net income from continuing operations, as specified under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3).
- Continued Trading Under Ticker “REFR”: There is no immediate effect on the listing or trading of the company’s common stock, which will continue to trade on The Nasdaq Capital Market under the symbol REFR.
- Compliance Period: REFR has been provided with 180 calendar days—until November 30, 2026—to regain compliance for both the minimum bid price and MVLS requirements.
- Regaining Compliance:
- For the minimum bid price: The closing bid must be at least \$1.00 per share for at least 10 consecutive business days during the compliance period (Nasdaq may require a longer period at its discretion).
- For MVLS: The company must achieve a market value of listed securities of \$35 million or more for at least 10 consecutive business days during the compliance period.
- Potential Actions: The company may consider actions such as a reverse stock split to regain compliance. No assurances can be given that REFR will regain compliance with either requirement within the compliance period or that it will remain in compliance with other Nasdaq continued listing standards.
Implications for Shareholders
The receipt of dual deficiency notices from Nasdaq is a material and potentially price-sensitive event. If the company is unable to regain compliance within the stipulated period, its shares could be delisted from the Nasdaq Capital Market. Delisting could significantly impact the liquidity and valuation of REFR shares.
Investors should also note the company’s current non-compliance with alternative listing standards regarding stockholders’ equity and net income from continuing operations. The company’s management may need to implement corporate actions, such as a reverse stock split, or undertake other measures to regain compliance. However, there is no guarantee that such actions will be successful or that the company will avoid delisting.
What to Watch Next
- Updates from REFR regarding any planned measures to regain compliance.
- Nasdaq’s response if the company fails to meet compliance by November 30, 2026.
- Potential volatility in share price as the compliance deadline approaches.
- Any further disclosures regarding the company’s financial position and operational results.
Conclusion
This development is highly material for Research Frontiers Inc. and its investors. Shareholders should monitor company announcements closely and be aware of the significant risks, including possible delisting from Nasdaq, which could adversely affect share value and liquidity.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a qualified financial advisor before making investment decisions. The author and publisher are not responsible for any losses arising from reliance on this information.
